Activation of Sigma-1 Receptor Enhanced Pericyte Survival via the Interplay Between Apoptosis and Autophagy: Implications for Blood–Brain Barrier Integrity in Stroke
- 13 Downloads
Stroke is a cerebrovascular disorder that affects many people worldwide. Pericytes play an important role in stroke progression and recovery. The sigma-1 receptor (σ-1R) signaling pathway has been suggested as having promising neuroprotective potential in treating stroke; however, whether σ-1R activation regulates pericyte function remains unknown. The aim of this study was to elucidate the role of σ-1R and a novel σ-1R agonist in pericytes following ischemic stroke. An ischemic stroke animal model was induced by photothrombotic middle cerebral artery occlusion (pMCAO) in σ-1R knockout (KO) and wild-type (WT) mice. After pMCAO, there was significant pericyte loss and coverage in σ-1R KO mice compared with WT mice as determined using transmission electron microscopy, immunofluorescence staining, and western blot. Interestingly, a novel σ-1R agonist decreased infarct volume and blood–brain barrier damage with a concomitant amelioration of pericyte loss, as determined by western blot. Further studies indicated that cell apoptosis and autophagy were induced in an in vivo pMCAO ischemic stroke animal model and an in vitro oxygen glucose deprivation-treatment group. Inhibition of autophagy using a pharmacological approach significantly mitigated pericyte apoptosis, suggesting that autophagy was upstream of apoptosis in pericytes. Both in vivo and in vitro studies indicated that the σ-1R agonist significantly decreased cell apoptosis via inhibition of autophagy with a subsequent enhancement of pericyte survival. This study identified the unique roles for σ-1R in mediating pericyte survival via the regulation of the interplay between apoptosis and autophagy, suggesting that a novel σ-1R agonist may be a promising therapeutic agent for the treatment of stroke patients.
KeywordsStroke Sigma-1 receptor Blood–brain barrier Pericyte Apoptosis Autophagy
This work was supported by grants from the National Natural Science Foundation of China (Nos. 81761138048, 81673410, and 81603090), Jiangsu Innovation & Entrepreneurship Talent Program, Jiangsu Innovation & Entrepreneurship Team Program, National Key Research and Development Program of China (2017YFA0104303), and the Fundamental Research Funds for the Central Universities (Nos. 2242018K41007, 2242018K41059, 2242019K40133, and 2242019K40125).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
All institutional and national guidelines for the care and use of laboratory animals were followed.
- 7.del Zoppo GJ, Hallenbeck JM. Advances in the vascular pathophysiology of ischemic stroke. Thromb Res. 2000;98(3):73–81.Google Scholar
- 15.Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science. 1988;240(4849):219–21.Google Scholar
- 19.Aydar E, Palmer CP, Klyachko VA, Jackson MB. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron. 2002;34(3):399–410.Google Scholar
- 20.Zhang XJ, Liu LL, Jiang SX, Zhong YM, Yang XL. Activation of the zeta receptor 1 suppresses NMDA responses in rat retinal ganglion cells. Neuroscience. 2011;177:12–22. https://doi.org/10.1016/j.neuroscience.2010.12.064.Google Scholar
- 27.Yao H, Kim K, Duan M, Hayashi T, Guo M, Morgello S, et al. Cocaine hijacks sigma1 receptor to initiate induction of activated leukocyte cell adhesion molecule: implication for increased monocyte adhesion and migration in the CNS. J Neurosci. 2011;31(16):5942–55. https://doi.org/10.1523/JNEUROSCI.5618-10.2011.Google Scholar
- 29.Allahtavakoli M, Jarrott B. Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats. Brain Res Bull. 2011;85(3–4):219–24. https://doi.org/10.1016/j.brainresbull.2011.03.019.Google Scholar
- 30.Ruscher K, Inacio AR, Valind K, Rowshan Ravan A, Kuric E, Wieloch T. Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke. PLoS One. 2012;7(9):e45118. https://doi.org/10.1371/journal.pone.0045118.Google Scholar
- 31.Fisher M, Schaebitz W. An overview of acute stroke therapy: past, present, and future. Arch Intern Med. 2000;160(21):3196–206.Google Scholar
- 37.Zhang X, Wu F, Jiao Y, Tang T, Yang L, Lu C, et al. An increase of sigma-1 receptor in the penumbra neuron after acute ischemic stroke. J Stroke Cerebrovasc Dis. 2017;26(9):1981–7. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.06.013.Google Scholar
- 38.Bai Y, Zhang Y, Han B, Yang L, Chen X, Huang R, et al. Circular RNA DLGAP4 ameliorates ischemic stroke outcomes by targeting miR-143 to regulate endothelial-mesenchymal transition associated with blood-brain barrier integrity. J Neurosci. 2018;38(1):32–50. https://doi.org/10.1523/JNEUROSCI.1348-17.2017.Google Scholar
- 40.Sanchez-Blazquez P, Pozo-Rodrigalvarez A, Merlos M, Garzon J. The sigma-1 receptor antagonist, S1RA, reduces stroke damage, ameliorates post-stroke neurological deficits and suppresses the overexpression of MMP-9. Mol Neurobiol. 2018;55(6):4940–51. https://doi.org/10.1007/s12035-017-0697-x.Google Scholar
- 41.Goguadze N, Zhuravliova E, Morin D, Mikeladze D, Maurice T. Sigma-1 receptor agonists induce oxidative stress in mitochondria and enhance complex I activity in physiological condition but protect against pathological oxidative stress. Neurotox Res. 2017;35:1–18. https://doi.org/10.1007/s12640-017-9838-2.Google Scholar
- 44.Melgar MA, Rafols J, Gloss D, Diaz FG. Postischemic reperfusion: ultrastructural blood-brain barrier and hemodynamic correlative changes in an awake model of transient forebrain ischemia. Neurosurgery. 2005;56(3):571–81.Google Scholar
- 45.Dohgu S, Takata F, Yamauchi A, Nakagawa S, Egawa T, Naito M, et al. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res. 2005;1038(2):208–15. https://doi.org/10.1016/j.brainres.2005.01.027.Google Scholar
- 47.Takata F, Dohgu S, Yamauchi A, Sumi N, Nakagawa S, Naito M, et al. Inhibition of transforming growth factor-beta production in brain pericytes contributes to cyclosporin A-induced dysfunction of the blood-brain barrier. Cell Mol Neurobiol. 2007;27(3):317–28. https://doi.org/10.1007/s10571-006-9125-x.Google Scholar
- 51.Zhou YF, Li PC, Wu JH, Haslam JA, Mao L, Xia YP, et al. Sema3E/PlexinD1 inhibition is a therapeutic strategy for improving cerebral perfusion and restoring functional loss after stroke in aged rats. Neurobiol Aging. 2018;70:102–16. https://doi.org/10.1016/j.neurobiolaging.2018.06.003.Google Scholar
- 52.Goyagi T, Goto S, Bhardwaj A, Dawson VL, Hurn PD, Kirsch JR. Neuroprotective effect of sigma(1)-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is linked to reduced neuronal nitric oxide production. Stroke. 2001;32(7):1613–20.Google Scholar
- 53.Goyagi T, Bhardwaj A, Koehler RC, Traystman RJ, Hurn PD, Kirsch JR. Potent sigma 1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine provides ischemic neuroprotection without altering dopamine accumulation in vivo in rats. Anesth Analg. 2003;96(2):532–8 table of contents.Google Scholar
- 54.Shen YC, Wang YH, Chou YC, Liou KT, Yen JC, Wang WY, et al. Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. J Neurochem. 2008;104(2):558–72. https://doi.org/10.1111/j.1471-4159.2007.05058.x.Google Scholar